Suppr超能文献

新辅助放化疗治疗食管胃结合部腺癌患者预后模型的建立:一项真实世界研究。

Establishment of prognostic models for adenocarcinoma of oesophagogastric junction patients with neoadjuvant chemoradiotherapy: a real-world study.

机构信息

Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Department of Radiation Oncology, Peking University Cancer Hospital and Institute, Beijing, 100142, People's Republic of China.

Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Department of Medical Imaging, Peking University Cancer Hospital and Institute, Beijing, 100142, People's Republic of China.

出版信息

Radiat Oncol. 2022 Mar 3;17(1):45. doi: 10.1186/s13014-022-02016-3.

Abstract

BACKGROUND

Multimodal therapies based on surgical resection have been recommended for the treatment of adenocarcinoma of the oesophagogastric junction (AEG). We aimed to evaluate prognostic factors in AEG patients receiving neoadjuvant chemoradiotherapy and to build predictive models.

METHODS

T3 - T4N + M0 AEG patients with resectable Siewert type II/III tumours were enrolled in this study. All patients underwent neoadjuvant chemoradiation, followed by radical surgery or systemic therapy according to clinical response. Survival analysis was performed using the Kaplan-Meier method; multivariate analysis using the Cox proportional hazards method was also conducted. The Harrell concordance index (C-index) was used to test the prognostic value of models involving prognostic factors, and consistency between actual and predicted survival rates was evaluated by calibration curves.

RESULTS

From February 2009 to February 2018, 79 patients were treated with neoadjuvant chemoradiotherapy; 60 patients of them underwent radical surgery. The R0 resection rate was 98.3%, and 46.7% of patients achieved a major pathologic response (MPR), namely, a residual tumour issue less than 10%. The 5-year overall survival (OS) rate was 63%, and the 5-year progression-free survival (PFS) rate was 48%. The incidence of grade 3 complications was 21.5%, and no grade 4 complications were reported. According to the results of univariate and multivariate analyses, we included the neutrophil-lymphocyte ratio (NLR), prognostic nutrition index (PNI), eosinophilic granulocyte (EOS) and postoperative pathologic stage in nomogram analysis to establish prediction models for OS and PFS; the C-index of each model was 0.814 and 0.722, respectively. Both the C-index and calibration curves generated to validate consistency between the actual and predicted survival indicated that the models were well calibrated and of good predictive value.

CONCLUSIONS

AEG patients achieved favourable downstaging and pathologic response after neoadjuvant chemoradiation, with acceptable adverse effects. Inflammation-based and nutrition-related factors and postoperative pathologic stage had a significant influence on OS and PFS, and the predictive value was verified through prognostic models.

摘要

背景

基于手术切除的多模态疗法已被推荐用于治疗食管胃结合部腺癌(AEG)。我们旨在评估接受新辅助放化疗的 AEG 患者的预后因素,并建立预测模型。

方法

本研究纳入了可切除的 Siewert Ⅱ/Ⅲ型肿瘤的 T3-T4N+M0 AEG 患者。所有患者均接受新辅助放化疗,根据临床反应行根治性手术或全身治疗。采用 Kaplan-Meier 法进行生存分析;采用 Cox 比例风险法进行多因素分析。采用 Harrell 一致性指数(C 指数)检验包含预后因素的模型的预后价值,并通过校准曲线评估实际生存率与预测生存率之间的一致性。

结果

2009 年 2 月至 2018 年 2 月,79 例患者接受了新辅助放化疗,其中 60 例患者行根治性手术。R0 切除率为 98.3%,46.7%的患者获得了主要病理缓解(MPR),即残留肿瘤问题小于 10%。5 年总生存率(OS)为 63%,5 年无进展生存率(PFS)为 48%。3 级并发症发生率为 21.5%,无 4 级并发症报告。根据单因素和多因素分析的结果,我们将中性粒细胞与淋巴细胞比值(NLR)、预后营养指数(PNI)、嗜酸性粒细胞(EOS)和术后病理分期纳入列线图分析,建立了 OS 和 PFS 的预测模型;各模型的 C 指数分别为 0.814 和 0.722。通过验证实际生存与预测生存之间一致性的 C 指数和校准曲线表明,这些模型具有良好的校准度和预测价值。

结论

AEG 患者在接受新辅助放化疗后获得了良好的降期和病理缓解,且不良反应可接受。基于炎症和营养的因素以及术后病理分期对 OS 和 PFS 有显著影响,并通过预后模型得到验证。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/575a/8896317/f167de945a12/13014_2022_2016_Fig1_HTML.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验